Bayer (0P6S) Receives a Buy from Barclays
In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Bayer, with a price target of €50.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pitman CFA covers the Healthcare sector, focusing on stocks such as UCB SA, Recordati Industria Chimica e Farmaceutica SPA, and Sartorius. According to TipRanks, Pitman CFA has an average return of 13.3% and a 62.33% success rate on recommended stocks.
In addition to Barclays, Bayer also received a Buy from J.P. Morgan’s Richard Vosser in a report issued today. However, on February 25, UBS maintained a Hold rating on Bayer (LSE: 0P6S).
0P6S market cap is currently €39.9B and has a P/E ratio of -201.54.
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer: Dose for expansion in PAnTHa study successfully identified
- Bayer reports final results from Phase III PEACE-3 trial of XOFIGO
- Law firms urge judge to delay review of proposed Bayer settlement, Reuters says
- Bayer files false advertising suit against J&J and Janssen Biotech
- 0P6S Earnings Report this Week: Is It a Buy, Ahead of Earnings?
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.